Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mary Jane Hinrichs

Choice of Starting Dose for Biopharmaceuticals in First-In-Human Phase I Cancer Clinical Trials

Oncologist

English

Design and Characterization of Homogenous Antibody-Drug Conjugates With a Drug-To-Antibody Ratio of One Prepared Using an Engineered Antibody and a Dual-Maleimide Pyrrolobenzodiazepine Dimer

English

Related publications

Phase I Cancer Clinical Trials

British Journal of Cancer

Cancer Research

Oncology

2007

English

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Journal of the Royal Statistical Society. Series C: Applied Statistics

English

Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials

Nucleic Acid Therapeutics

English

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

British Journal of Cancer

Cancer Research

Oncology

2009

English

Clinical Outcomes and Survival of Advanced Renal Cancer Patients in Phase I Clinical Trials

Clinical Genitourinary Cancer

Oncology

Urology

2014

English

Determination of the Starting Dose in the First-In-Human Clinical Trials With Monoclonal Antibodies: A Systematic Review of Papers Published Between 1990 and 2013

Drug Design, Development and Therapy

Drug Discovery

Pharmacology

Pharmaceutical Science

2016

English

P1.01-26 Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials

Journal of Thoracic Oncology

English

The Role of Age on Dose-Limiting Toxicities (DLTs) in Phase I Dose-Escalation Trials.

Journal of Clinical Oncology

English

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mary Jane Hinrichs

Choice of Starting Dose for Biopharmaceuticals in First-In-Human Phase I Cancer Clinical Trials

Design and Characterization of Homogenous Antibody-Drug Conjugates With a Drug-To-Antibody Ratio of One Prepared Using an Engineered Antibody and a Dual-Maleimide Pyrrolobenzodiazepine Dimer

Related publications

Phase I Cancer Clinical Trials

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

Clinical Outcomes and Survival of Advanced Renal Cancer Patients in Phase I Clinical Trials

Determination of the Starting Dose in the First-In-Human Clinical Trials With Monoclonal Antibodies: A Systematic Review of Papers Published Between 1990 and 2013

P1.01-26 Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials

The Role of Age on Dose-Limiting Toxicities (DLTs) in Phase I Dose-Escalation Trials.

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience